We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ABT.MX

Price
2194.99
Stock movement down
-169.61 (-7.17%)
Company name
Abbott Laboratories
Exchange
(MX
,
Currency
MXN
)
Sector
Healthcare >
Medical Devices
Market cap
3816.81B
Ent value
3842.21B
Price/Sales
87.06
Price/Book
74.45
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
273.08
Forward P/E
-
PEG
-
EPS growth
29.91%
1 year return
-7.30%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-12-12

DIVIDENDS

ABT.MX does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E273.08
Price to OCF418.56
Price to FCF551.80
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales87.06
Price to Book74.45
EV to Sales87.64

FINANCIALS

Per share

Loading...
Per share data
Current share count1.74B
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash7.51B
Net receivables8.14B
Total current assets24.84B
Goodwill23.97B
Intangible assets5.59B
Property, plant and equipment24.82B
Total assets84.18B
Accounts payable4.12B
Short/Current long term debt0.00
Total current liabilities14.58B
Total liabilities32.92B
Shareholder's equity51.26B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2194.99
Daily high2194.99
Daily low2194.99
Daily Volume0K
All-time high2930.00
1y analyst estimate-
Beta0.72
EPS (TTM)-
Dividend per share0.00
Ex-div date15 Oct 2025
Next earnings date21 Jan 2026

Downside potential

Loading...
Downside potential data
ABT.MXS&P500
Current price drop from All-time high-25.09%-
Highest price drop-25.09%-19.00%
Date of highest drop10 Dec 20258 Apr 2025
Avg drop from high-15.91%-2.64%
Avg time to new high-6 days
Max time to new high295 days89 days
COMPANY DETAILS
ABT.MX (Abbott Laboratories) company logo
Marketcap
3816.81B
Marketcap category
Large-cap
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Employees
114000
Investor relations
-
CEO
Country
Mexico
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
December 13, 2025
Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 63 cents per share, an increase of 6.8%. The company's quarterly dividend payout...
December 12, 2025
HOLX's Diagnostics gains accelerate as U.S. molecular testing drives growth and new Panther Fusion and Genius platform approvals widen its runway.
December 12, 2025
The autoimmune disease diagnosis market is poised to grow from USD 5.57 billion in 2025 to USD 8.98 billion by 2031, exhibiting a CAGR of 8.3%. Key growth drivers include rising autoimmune disorder pr...
December 12, 2025
In early December 2025, Medtronic’s board approved a US$0.71 per-share cash dividend for the third quarter of fiscal 2026, payable on January 16, 2026, and the company secured FDA clearance for its Hu...
December 12, 2025
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing mar...
December 12, 2025
The baby-formula giant is pressuring Washington with a high-stakes ultimatum as lawsuits mount and regulators watch.
December 11, 2025
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
December 11, 2025
Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector. With improving volume patterns, accelerating relativ...
December 9, 2025
Key Insights Significantly high institutional ownership implies Abbott Laboratories' stock price is sensitive to their...
December 9, 2025
Next page